Molecular Current Deferred Revenue vs Net Receivables Analysis
MOLN Stock | USD 3.78 0.09 2.33% |
Molecular Partners financial indicator trend analysis is infinitely more than just investigating Molecular Partners recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Molecular Partners is a good investment. Please check the relationship between Molecular Partners Current Deferred Revenue and its Net Receivables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Current Deferred Revenue vs Net Receivables
Current Deferred Revenue vs Net Receivables Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Molecular Partners Current Deferred Revenue account and Net Receivables. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Molecular Partners' Current Deferred Revenue and Net Receivables is 0.42. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Molecular Partners AG, assuming nothing else is changed. The correlation between historical values of Molecular Partners' Current Deferred Revenue and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Molecular Partners AG are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Current Deferred Revenue i.e., Molecular Partners' Current Deferred Revenue and Net Receivables go up and down completely randomly.
Correlation Coefficient | 0.42 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Current Deferred Revenue
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.Net Receivables
Most indicators from Molecular Partners' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Molecular Partners current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, Molecular Partners' Sales General And Administrative To Revenue is very stable compared to the past year. As of the 20th of May 2024, Enterprise Value Over EBITDA is likely to grow to 1.22, while Selling General Administrative is likely to drop about 12.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 548K | 605K | 49K | 46.6K | Depreciation And Amortization | 2.7M | 3.5M | 2.4M | 2.1M |
Molecular Partners fundamental ratios Correlations
Click cells to compare fundamentals
Molecular Partners Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Molecular Partners fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 104.9M | 187.5M | 172.7M | 262.3M | 198.4M | 193.3M | |
Other Current Liab | 7.0M | 10.7M | 12.5M | 8.6M | 8.5M | 6.9M | |
Total Current Liabilities | 28.6M | 57.7M | 46.9M | 17.3M | 14.4M | 13.7M | |
Total Stockholder Equity | 54.1M | 107.2M | 107.3M | 235.2M | 176.4M | 137.3M | |
Property Plant And Equipment Net | 4.2M | 9.4M | 8.1M | 7.2M | 5.7M | 4.7M | |
Current Deferred Revenue | 18.3M | 42.9M | 28.3M | 6.4M | 4.3M | 4.1M | |
Net Debt | (73.2M) | (126.5M) | (65.8M) | (83.1M) | (183.2M) | (192.4M) | |
Retained Earnings | (130.9M) | (195.2M) | (251.0M) | (127.8M) | (191.8M) | (182.2M) | |
Accounts Payable | 2.0M | 2.8M | 4.9M | 997K | 410K | 389.5K | |
Cash | 75.7M | 133.7M | 71.8M | 87.9M | 186.9M | 103.0M | |
Non Current Assets Total | 5.0M | 9.7M | 8.5M | 7.5M | 5.9M | 5.0M | |
Cash And Short Term Investments | 95.1M | 173.7M | 132.8M | 249.1M | 186.9M | 175.8M | |
Net Receivables | 2.5M | 2.8M | 25.7M | 1.7M | 1.7M | 1.7M | |
Common Stock Total Equity | 2.1M | 2.1M | 2.2M | 2.9M | 3.4M | 2.3M | |
Common Stock Shares Outstanding | 21.4M | 25.0M | 31.0M | 33.3M | 32.8M | 26.0M | |
Liabilities And Stockholders Equity | 104.9M | 187.5M | 172.7M | 262.3M | 198.4M | 193.3M | |
Non Current Liabilities Total | 22.2M | 22.7M | 18.5M | 9.8M | 7.5M | 7.1M | |
Inventory | (51.6M) | (486K) | (199K) | (86.7M) | (78.1M) | (74.2M) | |
Other Current Assets | 2.8M | 1.5M | 92.4M | 3.9M | 3.8M | 3.6M | |
Other Stockholder Equity | 182.8M | 299.5M | 355.0M | 360.3M | 364.5M | 250.9M | |
Total Liab | 50.8M | 80.3M | 65.4M | 27.1M | 21.9M | 40.7M | |
Property Plant And Equipment Gross | 4.2M | 9.4M | 20.9M | 21.9M | 22.0M | 23.1M | |
Total Current Assets | 99.9M | 177.8M | 164.2M | 254.8M | 192.5M | 188.3M | |
Intangible Assets | 772K | 347K | 330K | 271K | 212K | 245.5K | |
Common Stock | 2.2M | 2.9M | 3.2M | 3.6M | 3.6M | 2.7M | |
Short Term Investments | 19.4M | 40M | 61M | 161.2M | 119.6M | 125.6M | |
Other Liab | 20.9M | 16.6M | 13.7M | 6.2M | 5.6M | 5.3M | |
Net Tangible Assets | 53.4M | 106.9M | 107.0M | 234.9M | 270.1M | 283.6M | |
Net Invested Capital | 54.1M | 107.2M | 107.3M | 235.2M | 176.4M | 139.6M | |
Net Working Capital | 71.3M | 120.1M | 117.3M | 237.5M | 178.0M | 152.3M | |
Property Plant Equipment | 4.2M | 9.4M | 8.1M | 7.2M | 8.3M | 5.9M | |
Capital Stock | 2.2M | 2.9M | 3.2M | 3.6M | 3.6M | 3.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Molecular Stock analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.215 | Quarterly Revenue Growth (0.62) | Return On Assets (0.17) | Return On Equity (0.30) |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.